PSMA PyL dRT – Prostate Cancer
Lay Title: A randomized imaging study of PSMA PET scan before definitive radiation therapy in patients with unfavorable IR or HR prostate cancer
Technical Title: Phase 3 randomized trial of PSMA PET prior to definitive radiation therapy for intermediate-or high-risk prostate cancer [PSMA dRT]
Disease Type: Intermediate- or high risk Prostate Cancer
Basic information: The purpose of this research study is to determine the outcome of definitive radiation therapy (dRT) in patients with unfavorable intermediate (IR) or high-risk (HR) prostate cancer (PCa) with versus without planning based on PSMA PET.
Research Procedures: This trial will enroll 312 patients with prostate cancer. Each patient will be randomized to either get the PSMA PET/CT scan prior to undergoing definitive prostate radiotherapy or to proceed with standard definitive prostate radiotherapy as initially planned without the PSMA scan (50/50 chance). The whole radiation therapy management (consultations, treatment, follow-up) is performed at the facility of the treating radiation oncologist. After the treatment, enrolled patient can be contacted by the UCLA nuclear medicine team to see what their PSA levels are, the results of any imaging they may have had, and if they have received any additional treatment for prostate cancer.
For patients randomized to the PSMA PET group, the PET/CT scan during the visit in the UCLA nuclear medicine clinic will be free of charge.
For patients randomized to the standard group, there is no procedure in the UCLA nuclear medicine clinic as part of the trial and therefore no cost to the patient.
More detailed information on clinicaltrials.gov
For More Detailed Information, Contact: